全文获取类型
收费全文 | 16153篇 |
免费 | 1095篇 |
国内免费 | 98篇 |
专业分类
耳鼻咽喉 | 161篇 |
儿科学 | 535篇 |
妇产科学 | 363篇 |
基础医学 | 2377篇 |
口腔科学 | 271篇 |
临床医学 | 1411篇 |
内科学 | 3916篇 |
皮肤病学 | 493篇 |
神经病学 | 1631篇 |
特种医学 | 343篇 |
外科学 | 1634篇 |
综合类 | 45篇 |
一般理论 | 7篇 |
预防医学 | 1347篇 |
眼科学 | 318篇 |
药学 | 1194篇 |
中国医学 | 45篇 |
肿瘤学 | 1255篇 |
出版年
2024年 | 24篇 |
2023年 | 211篇 |
2022年 | 520篇 |
2021年 | 916篇 |
2020年 | 429篇 |
2019年 | 669篇 |
2018年 | 720篇 |
2017年 | 448篇 |
2016年 | 514篇 |
2015年 | 621篇 |
2014年 | 757篇 |
2013年 | 988篇 |
2012年 | 1364篇 |
2011年 | 1356篇 |
2010年 | 821篇 |
2009年 | 631篇 |
2008年 | 982篇 |
2007年 | 949篇 |
2006年 | 860篇 |
2005年 | 778篇 |
2004年 | 660篇 |
2003年 | 571篇 |
2002年 | 525篇 |
2001年 | 105篇 |
2000年 | 90篇 |
1999年 | 99篇 |
1998年 | 99篇 |
1997年 | 89篇 |
1996年 | 57篇 |
1995年 | 38篇 |
1994年 | 44篇 |
1993年 | 31篇 |
1992年 | 55篇 |
1991年 | 34篇 |
1990年 | 34篇 |
1989年 | 16篇 |
1988年 | 20篇 |
1987年 | 18篇 |
1986年 | 25篇 |
1985年 | 19篇 |
1984年 | 8篇 |
1983年 | 18篇 |
1982年 | 12篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1974年 | 14篇 |
1973年 | 6篇 |
1971年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Primo N Lara Walter M Stadler Jeff Longmate David I Quinn Jason Wexler Marta Van Loan Przemyslaw Twardowski Paul H Gumerlock Nicholas J Vogelzang Everett E Vokes Heinz Josef Lenz James H Doroshow David R Gandara 《Clinical cancer research》2006,12(5):1556-1563
BACKGROUND: BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the dose-limiting arthritis of older MMPIs. We conducted a randomized phase II trial of two doses of BMS-275291 (1,200 versus 2,400 mg) in hormone-refractory prostate cancer (HRPC) patients with bone metastases to probe for a dose-response relationship and to assess differential toxicities. Serial serum and urine specimens were collected to assess for markers of bone metabolism. METHODS: The primary end point was 4-month progression-free survival (PFS). Eligibility criteria included documentation of androgen-independent disease (including anti-androgen withdrawal), skeletal metastasis, adequate end-organ function and performance status, and no more than one prior chemotherapy regimen. Patients were randomized to 1,200 mg orally once daily (arm A) or 1,200 mg orally twice daily (arm B). Response was assessed every 56 days. RESULTS: Eighty patients were enrolled: 39 in arm A and 41 in arm B. There were no responders by prostate-specific antigen or measurable disease to treatment. Stable disease was noted at 8 weeks in 39% of patients in arm A and in 17% of patients in arm B. Progression of disease at 8 weeks was seen in 61% of patients in arm A versus 83% of patients in arm B. Median survival time was 21.6 months (95% confidence interval, 17.5; not reached), whereas median PFS time was 1.8 months (95% confidence interval 1.74; 2) for all patients. Patients in arm A had a median survival time that was not reached, whereas patients on arm B has a median survival time of 21 months (P = 0.2). PFS at 4 months favored arm A: 22% versus 10% (log-rank, P = 0.008). Grade 3 toxicities occurred in 5 (13%) patients in arm A and in 9 (22%) patients in arm B. Grade 4 toxicities were uncommon (only 4% of patients): one each of thrombosis, fatigue, and motor neuropathy was seen in the arm B. Bone marker studies showed that baseline serum levels of N-telopeptide, osteocalcin, procollagen I NH2-terminal propeptide, and PICP had prognostic significance for PFS and/or overall survival. CONCLUSIONS: Regardless of dose schedule, BMS-275291 was well tolerated in HRPC patients and had no dose-limiting arthritis. Toxicities differed modestly according to the dose schedule employed. As overall survival and PFS favored the once daily schedule, this dose schedule is recommended for future studies. Baseline markers of bone metabolism may have prognostic value in HRPC patients with bone metastases. 相似文献
992.
2型糖尿病的预测性遗传学检测可能引起不切实际的期望 总被引:1,自引:0,他引:1
A Cecile JW Janssens Marta Gwinn Rodoffo Valdez KM Venkat Narayan Muin J Khoury 谢超 《英国医学杂志》2006,9(6):331-332
今年年初,《纽约时报》头版头条报道了TCF7L2基因变异与2型糖尿病相关。主要研究者KariStefansson告诉《纽约时报》,这一发现可能会导致一种新的诊断性检测法产生,用于识别携带糖尿病变异基因的个体。他说,这将促使那些知道自己有糖尿病高风险的人们避免采取引起糖尿病的生活方式。一位苏格兰科学家领导着该研究小组,《格拉斯哥先驱报》曾率先报道他们的工作,“糖尿病致病基因的发现将有助于科学家治疗糖尿病”。 相似文献
993.
Pradhan M Meyers KE Guttenberg M Kaplan BS 《Pediatric nephrology (Berlin, Germany)》2000,14(8-9):862-871
An unusual sequence of the clinical manifestations of microvascular disease is described in a 15 year-old girl. She initially
presented with acute renal failure caused by a crescentic glomerulonephritis associated with positive tests for MPO-ANCA.
Eighteen months later she had pulmonary hemorrhage and respiratory failure. An open lung biopsy showed granulomas that were
diagnostic for Wegener granulomatosis. We discuss the diagnostic dilemmas faced in attempts to distinguish infective causes
of pulmonary granulomas, such as tuberculosis or fungi, from granulomas associated with vasculitis, in a patient previously
treated with immunosuppressive therapy.
Received: 4 August 1999 / Revised: 28 October 1999 / Accepted: 3 January 2000 相似文献
994.
995.
Dubravka Tislari? Bojana Brajenovi?-Mili? Smiljana Risti? Visnja Latin Marta Zuvi?-Butorac Josip Baci? Marijan Petek Miljenko Kapovi? 《Fetal diagnosis and therapy》2002,17(1):17-21
OBJECTIVE: To evaluate the impact of smoking and number of previous births on maternal serum levels of alpha-fetoprotein and free beta-subunit of human chorionic gonadotropin (free beta-hCG). METHODS: The study included 3,252 completed unaffected singleton pregnancies that proceeded beyond 37 weeks' gestation and resulted with a birth of healthy child. Smoking status of mothers and data concerning gravidity and parity were collected at the sampling date. Serum markers were measured between 13 and 22 gestational weeks, corrected for maternal weight, and converted to multiples of median (MoM) for unaffected pregnancy of the corresponding gestational age. Median MoM values for both markers were examined in relation to both: smoking habits and number of previous births. RESULTS: Smokers had significantly decreased free beta-hCG MoM values compared to nonsmokers (p < 0.001). The median levels showed a negative relationship with the number of previous births. The significance of a decreasing trend was proved, both in smokers (p < 0.001) and nonsmokers (p < 0.001). The median maternal serum alpha-fetoprotein MoM values did not show any significant dependence, neither with regard to smoking (p = 0.65) nor with regard to parity (p = 0.07). CONCLUSIONS: The recommendable adjustment of serum markers to smoking habits, especially concerning the free beta-hCG levels, would be worthwhile. The evidence of the coexisting influence of parity on serum levels of free beta-hCG, both in smokers and nonsmokers, should perhaps be a stimulus for reconsideration of which corrections the screening performance is dependent on. 相似文献
996.
Marta Salido Francesc Solé Ignasi Tusquets Josep M. Corominas Blanca Espinet MaLluïsa Mariñoso Teresa Baró MaCarmen Vela Xavier Fabregat Sergi Serrano 《Clinical & translational oncology》2002,4(5):255-259
The HER2/neu protooncogene is expressed in the breast, ovarian, gastric and prostatic tumors. Studies done in a number of laboratories have demostrated that 25%–30% of breast cancer contain overexpression of HER2/neu gene. A comparative analysis of the amplification and overexpression of HER2/neu using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) was performed to determine the correlation between both techniques. In this study, FISH with HER2/neu probe (Path Vysion) is compared to immunohistochemistry (rabbit anti-human c-erbB-2-DAKO) in a series of 101 prospective human breast cancer specimens. Among 25 patients with score of IHC 3+, 23 (92%) were detected amplified by FISH and in two cases we found overexpression (3+) but without gene amplification. Out of 46 cases with 2+ by IHC, we found 43 not amplified, two moderately amplified (<10 copies) and one highly amplified (>10 copies) (6.5%). No patient with IHC O or 1+, presented amplification of HER2/neu. A good correlation between both techniques was found. FISH technique should have clinical utillity overoat in cases with 2+. 相似文献
997.
Hiroya Kobayashi Ryusuke Omiya Marta Ruiz Eduardo Huarte Pablo Sarobe Juan José Lasarte Maite Herraiz Bruno Sangro Jesús Prieto Francisco Borras-Cuesta Esteban Celis 《Clinical cancer research》2002,8(10):3219-3225
PURPOSE: The product of the carcinoembryonic antigen (CEA) gene is an attractive candidate for T-cell-based immunotherapy because it is frequently expressed in epithelial solid carcinomas. Although many CEA peptide epitopes capable of stimulating CTLs have been identified, no MHC class II-restricted T helper epitope has yet been reported. Experimental Design: The amino acid sequence of CEA was examined for the presence of potential T helper epitopes, and candidate peptides were used to stimulate in vitro T-cell responses. RESULTS: We describe here that using an algorithm to identify promiscuous helper T-cell epitopes, a peptide of CEA occupying residue positions 653 to 667 (CEA(653-667)), was effective in inducing in vitro T helper responses in the context of the HLA-DR4, HLA-DR7, and HLA-DR 9 alleles. Most significantly, some of the peptide-reactive helper T lymphocytes were also capable of recognizing naturally processed antigen in the form of recombinant CEA protein or cell lysates from tumors that express CEA. Interestingly, the newly identified helper T-cell epitope was found to overlap with a previously described HLA-A24-restricted CTL epitope, CEA(652-660), which could facilitate the development of a therapeutic vaccine capable of eliciting both CTL and T helper responses in patients suffering from epithelial carcinomas. CONCLUSION: These results indicate that T helper lymphocytes are capable of recognizing CEA as a tumor antigen and that epitope CEA(653-667) could be used for immunotherapy against tumors expressing CEA. 相似文献
998.
Merc Pineda Javier Arpa Raquel Montero Asuncin Aracil Francisco Domínguez Marta Galvn Anna Mas Loreto Martorell Cristina Sierra Nuria Brandi Elena García-Arumí Miquel Rissech Daniel Velasco Juan A. Costa Rafael Artuch 《European journal of paediatric neurology》2008,12(6):470-475
BACKGROUND: Antioxidant therapy is a new therapeutical approach for patients with Friedreich ataxia. AIMS: To assess the effectiveness of long-term idebenone treatment in Friedreich ataxia patients. METHODS: An open-labelled prospective study. Ten paediatric patients (age range 8-18 years) and 14 adults (age range 18-46 years) with genetic diagnosis of Friedreich ataxia were treated with idebenone (5-20mg/kg/day) for 3-5 years. Neurological evolution was evaluated using the International Cooperative Ataxia Rating Scale (ICARS), and cardiological outcomes using echocardiography. RESULTS: In paediatric patients, no significant differences were observed in ICARS scores and echocardiographic measurements when comparing baseline status and after 5 years of follow-up. Concerning adult cases, ICARS scores showed a significant increase in neurological dysfunctions during 3 years of therapy (Wilcoxon test, p=0.005), while echocardiographic measurements remained unchanged. CONCLUSIONS: Our results indicate that longer-term idebenone treatment prevented progression of cardiomyopathy in both paediatric and adult patients, whereas its stabilizing effect on neurological dysfunction was present only in the paediatric population, mainly before puberty. This suggests that the age at which idebenone treatment is initiated may be an important factor in the effectiveness of the therapy. 相似文献
999.
Ariel L Rivas Kevin L Anderson Roberta Lyman Stephen D Smith Steven J Schwager 《International journal of health geographics》2008,7(1):58
Background
A method that assesses bacterial spatial dissemination was explored. It measures microbial genotypes (defined by electrophoretic patterns or EP), host, location (farm), interfarm Euclidean distance, and time. Its proof of concept (construct and internal validity) was evaluated using a dataset that included 113 Staphylococcus aureus EPs from 1126 bovine milk isolates collected on 23 farms between 1988 and 2005. 相似文献1000.
We report a case of primary splenic T-cell lymphoma that posed difficult problems in differential diagnosis with erythrophagocytic T-gamma lymphoma and inflammatory pseudotumor of the spleen. The need for immunophenotypic and molecular studies for establishing the correct diagnosis and the importance of early detection and treatment, is emphasized in the light of the relatively good prognosis of splenic lymphoma, diagnosed in the early stages of disease. 相似文献